Sage Group News

Sage Represents Respira Therapeutics - Opportunity to License RT234, A Late Stage Asset for Pulmonar

The Sage Group is working with Respira Therapeutics (“Respira”; to identify clinical and commercial development partners for its later stage, highly novel asset for treatment of serious cardiopulmonary disease. Respira’s initial pipeline is targeting two indications with large unmet medical needs, with market potentials likely in excess of $1Bn each. Respira is a privately funded US-based company focused on treatment of cardiopulmonary disease using a novel delivery method of its lead compound RT234 (vardenafil) to the small airways of the lungs.Respira's approach combines state-of-the-art proprietary inhaled drug formulation and dry-powder inhaler device tec

Sage Represents DBM: An Opportunity to Acquire or Partner with a Revenue Generating Pre-Clinical CRO

The Sage Group is pleased to announce it is representing Discovery Biomed (“DBM”; DBM is a revenue-generating pre-clinical CRO based in Birmingham, Alabama focused on integrating biologically- and disease-relevant human cell cultures and lines into all relevant steps of Drug Discovery. Please request from Sage a non-confidential Information Memorandum on DBM. DBM is the one of the first companies to enable extension of preclinical testing to human cells and cell models including those derived from both healthy and diseased tissue. DBM owns a defined niche in the Humanized Drug Discovery space that sets them apart from the competition in the creation and bioassa